Avantium to supply PEF to BIOVOX for pharmaceutical applications

Avantium N.V., a leading company in renewable and circular polymer materials, has signed a capacity reservation agreement with BIOVOX, a pioneer in sustainable healthcare plastics, for polyethylene furanoate (PEF) in pharmaceutical applications.

Avantium offers PEF for pharmaceutical sector.

Avantium has developed a proprietary process to produce furandicarboxylic acid (FDCA), the key building block for PEF, branded as releaf. Following the completion of the world’s first commercial FDCA plant in Delfzijl, the Netherlands, in October 2024, Avantium has commenced the start-up of the plant.

“We look forward to leveraging this cutting-edge material to address demanding critical applications, where renewable polymers have not been able to deliver yet. We can even deliver significant performance advantages over currently used materials which helps to reduce material use further,” said Dr. Julian Lotz, CEO of BIOVOX.

This FDCA Flagship Plant is vital to Avantium's YXY Technology licensing strategy, enabling the company to offer technology licenses to industrial partners and develop projects to produce FDCA and PEF on an industrial scale across the globe.

Commercial demand for PEF is a crucial factor in licensing discussions. Over the past year, Avantium has signed multi-year capacity reservation agreements. The agreement with BIOVOX further demonstrates Avantium's ability to meet the commercial demand for FDCA and PEF effectively.

“With PEF from future licensed plants, we are able to offer BIOVOX a high-performance, environmentally friendly solution that meets the stringent demands of pharmaceutical packaging,” added Bineke Posthumus, Commercial Director of Avantium Renewable Polymers.